NCT01819935CompletedNot Applicable
Clinical Outcomes Among a National Veterans Affairs Methicillin Resistant Staphylococcus Aureus (MRSA) Pneumonia Cohort Treated With Linezolid Or Vancomycin
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Pfizer
- Enrollment
- 5,271
- Primary Endpoint
- Time to 30-day Mortality
Study Overview
Brief Summary
The purpose of this non-interventional, retrospective study of existing data is to evaluate clinical outcomes related to Methicillin-resistant Staphylococcus aureus hospital based pneumonia by treatment and among subpopulations.
Detailed Description
All patients meeting inclusion/exclusion criteria from inpatient database from 1/1/02-9/30/10.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •MRSA and pneumonia cases by ICD-9 code identification.
- •Diagnosis included during inpatient stay.
- •Treatment initiation in hospital.
Exclusion Criteria
- •Death of discharge within 3 days of treatment initiation.
- •Exposure to other treatments with MRSA activity.
Arms & Interventions
linezolid (Zyvox)
Intervention: linezolid (Zyvox) (Drug)
Vancomycin
Intervention: vancomycin (Drug)
Outcomes
Primary Outcomes
Time to 30-day Mortality
Time Frame: Baseline (1 January 2001) up to 3559 Days (30 September 2010)
Time to death (all-cause mortality) occurring within 30 days of treatment initiation was reported. Mortality was assessed from admission vital status databases.
Secondary Outcomes
- Time to Therapy Change(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
- Time to Discharge From the Hospital(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
- Time to Transfer Out From the Intensive Care Unit (ICU)(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
- Time to Intubation(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
- Time to 30-day Re-admission(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
- Time to 30-day Methicillin-Resistant Staphylococcus Aureus (MRSA) Re-infection(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
- Clinical Success(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the RussiaHR+HER2- Advanced Breast CancerNCT06148506Novartis Pharmaceuticals376
Completed
Not Applicable
Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201Macular EdemaRetinal Vein OcclusionNCT02956330Clearside Biomedical, Inc.20
Completed
Not Applicable
Retrospective NIS to Evaluate the Patient Benefit of TESRetinitis PigmentosaNCT04983914Okuvision GmbH49
Completed
Not Applicable
A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive DiseaseRelapsed/Refractory Multiple MyelomaNCT02608515Genesis Pharma S.A.207
Completed
Not Applicable
A National Study of Clinical Results After Emergency Operation for Perforated DiverticulitisPerforated DiverticulitisNCT03332550Sahlgrenska University Hospital, Sweden669